Even if the implementation of the workforce reduction and cash preservation strategy announced in June 2026 provides the anticipated cost savings as expected, the Company will need additional funding to support its continuing operations, service its outstanding debt and pursue its development strategy.

filing / Jun 15, 2026 / receipt

Workforce Reduction and Strategic Restructuring On June 15, 2026, the Company announced the implementation of a plan to reduce its workforce by approximately 50 % to streamline operations and preserve cash.

filing / Jun 15, 2026 / receipt

Workforce Reduction and Strategic Restructuring On June 15, 2026, we announced the implementation of a plan to reduce our workforce by approximately 50% to streamline operations and preserve cash.

filing / Jun 15, 2026 / receipt

• a $2.7 million increase in personnel-related costs, including a $0.7 million increase in stock-based compensation, driven by increased headcount as the Company continues to scale its clinical operations, quality, medical affairs and manufacturing functions to support our LEGEND study of detalimogene, and increased bonus and contractor expenses; and

filing / Jun 15, 2026 / receipt

• a $5.3 million increase in personnel-related costs, including a $1.1 million increase in stock-based compensation, driven by increased headcount as the Company continues to scale its clinical operations, quality, medical affairs and manufacturing functions to support our LEGEND study of detalimogene, and increased bonus and contractor expenses; and

filing / Jun 15, 2026 / receipt

On December 29, 2022, the Company signed a lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC.

filing / Jun 15, 2026 / receipt

Even if the implementation of the workforce reduction and cash preservation strategy announced in June 2026 provides the anticipated cost savings as expected, the Company will need additional funding to support its continuing operations, service its outstanding debt and pursue its development strategy.

filing / Jun 15, 2026 / receipt

Workforce Reduction and Strategic Restructuring On June 15, 2026, the Company announced the implementation of a plan to reduce its workforce by approximately 50 % to streamline operations and preserve cash.

filing / Jun 15, 2026 / receipt

Workforce Reduction and Strategic Restructuring On June 15, 2026, we announced the implementation of a plan to reduce our workforce by approximately 50% to streamline operations and preserve cash.

filing / Jun 15, 2026 / receipt

• a $2.7 million increase in personnel-related costs, including a $0.7 million increase in stock-based compensation, driven by increased headcount as the Company continues to scale its clinical operations, quality, medical affairs and manufacturing functions to support our LEGEND study of detalimogene, and increased bonus and contractor expenses; and

filing / Jun 15, 2026 / receipt

• a $5.3 million increase in personnel-related costs, including a $1.1 million increase in stock-based compensation, driven by increased headcount as the Company continues to scale its clinical operations, quality, medical affairs and manufacturing functions to support our LEGEND study of detalimogene, and increased bonus and contractor expenses; and

filing / Jun 15, 2026 / receipt

On December 29, 2022, the Company signed a lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC.

filing / Jun 15, 2026 / receipt